 |
Scientific Milestone Expands Growth of Paxalisib Past Oncology and Triggers $2 Million Cost to Kazia
SYDNEY, Sept. 22, 2026 /PRNewswire/ — Kazia Therapeutics Restricted (NASDAQ: KZIA), an oncology-focused biotechnology firm creating therapies that selectively reprogram most cancers biology, restore anti-tumor immunity and overcome therapy resistance, at present introduced that Sovargen Co., Ltd., a biotechnology firm specializing in central nervous system (CNS) ailments that has solely licensed paxalisib from Kazia for the event and commercialization of paxalisib as a possible therapy for mTORopathy-related epilepsies, has dosed the primary affected person in a Section 1b/2a scientific trial evaluating paxalisib for the therapy of intractable epilepsy related to focal cortical dysplasia kind 2 (FCD T2) and tuberous sclerosis advanced (TSC). The dosing triggers a $2 million growth milestone fee to Kazia beneath the businesses’ unique licensing settlement.
Kazia and Sovargen entered into the settlement in March 2024, beneath which Sovargen is answerable for creating, manufacturing and commercializing paxalisib as a possible therapy for the mTORopathy-related epilepsies in all nations worldwide, excluding mainland China, Hong Kong, Macao and Taiwan. Underneath the settlement, Kazia is eligible to obtain extra milestone funds of as much as $17 million upon the achievement of additional growth and regulatory milestones, plus a share of sub-licensing revenues and royalties on internet gross sales of any merchandise incorporating paxalisib.
FCD T2 and TSC are uncommon, genetically pushed neurological issues through which somatic mutations within the PI3K/Akt/mTOR pathway, or mutations within the TSC1 or TSC2 genes, drive overactivation of the mTOR pathway and contribute to treatment-resistant seizures. There are at the moment no accredited therapies for FCD T2. Paxalisib is an oral, brain-penetrant twin inhibitor of PI3K and mTOR.
“This milestone displays the regular progress Sovargen is making in advancing paxalisib for sufferers with FCD T2 and TSC, two uncommon issues with important unmet want,” stated Dr. John Buddy II, CEO of Kazia Therapeutics. “Whereas our personal scientific focus for paxalisib stays in oncology, we’re happy to see its potential being explored in extra indications the place its mechanism of motion might deal with important unmet medical wants. We look ahead to the information generated by way of this examine as this system advances.”
“Households residing with FCD T2 and TSC have lengthy confronted restricted therapy choices, making the development of latest therapies essential,” stated Cheolwon Park, CEO of Sovargen. “Dosing the primary affected person is a major step for our program and displays the dedication of our crew and investigators in bringing this examine to life. As enrollment continues, we stay centered on executing a rigorous scientific trial and producing the information wanted to higher perceive paxalisib’s potential as a therapy for these uncommon neurological issues.”
About Kazia Therapeutics
Kazia Therapeutics (NASDAQ: KZIA) is an oncology-focused drug growth firm, based mostly in Sydney, Australia. The Firm’s lead asset, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to deal with a number of types of most cancers. Licensed from Genentech in late 2016, paxalisib is or has been the topic of over 15 scientific trials. A accomplished Section 2/3 examine in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational examine in pursuit of an ordinary approval. Different scientific trials involving paxalisib are ongoing in superior breast most cancers, mind metastases, diffuse midline gliomas, and first central nervous system lymphoma, with a number of of those trials having reported encouraging interim knowledge. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Meals and Drug Administration (FDA) in February 2018, and Quick Observe Designation (FTD) for glioblastoma in August 2020. Paxalisib was additionally granted FTD in July 2023 for the therapy of stable tumor mind metastases harboring PI3K pathway mutations together with radiation remedy. Moreover, paxalisib was granted Uncommon Pediatric Illness Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia can be creating EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Along with its clinical-stage packages, Kazia is advancing NDL2, a probably first-in-class intracellular PD-L1 protein degrader program focusing on a newly recognized mechanism of immunotherapy resistance and metastatic development, in addition to MSETC, a probably first-in-class SETDB1 inhibitor program meant to revive immune signaling in tumors which have turn into proof against immunotherapy, together with checkpoint inhibitors. Each packages are at the moment in preclinical growth. For extra data, please go to www.kaziatx.com or observe us on X @KaziaTx.
About Sovargen
Sovargen Co., Ltd. is a clinical-stage biotechnology firm based mostly in Korea, based in 2018 as a spin-out from the Korea Superior Institute of Science and Expertise (KAIST). The Firm is targeted on the invention and growth of medicines for uncommon and intractable neurological issues attributable to mind somatic mosaicism. The Firm’s lead scientific asset, SVG103 (paxalisib), is a mind penetrant twin PI3K/mTOR inhibitor in-licensed from Kazia Therapeutics for the therapy of mTORopathy-related epilepsies, together with focal cortical dysplasia kind II (FCD T2), tuberous sclerosis advanced (TSC), and hemimegalencephaly (HME) — circumstances through which mTOR pathway hyperactivation is the underlying explanation for drug-resistant seizures. SVG103 is at the moment being evaluated in a Section 1b/2a examine in grownup sufferers with FCD T2, TSC, and HME. SVG105 is an antisense oligonucleotide focusing on intractable epilepsies that has been out-licensed to a European international pharmaceutical firm for worldwide growth and commercialization. Sovargen’s pipeline is underpinned by its proprietary, built-in platform designed to find and develop therapeutics for intractable CNS ailments. The platform options SovarIN™ for figuring out disease-causing somatic mutations and therapeutic targets. SovarON™ for ASO design, screening, and optimization, and SovarUP™ for goal validation and preclinical efficacy analysis utilizing disease-relevant animal fashions and human organoid techniques. For extra data, please go to www.sovargen.com.
Ahead-Wanting Statements
This press launch incorporates forward-looking statements inside the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended. Ahead-looking statements are typically recognized by phrases resembling “anticipates,” “believes,” “expects,” “intends,” “plans,” “might,” “will,” “may,” “ought to,” “estimates,” “tasks,” “potential,” and comparable expressions. These forward-looking statements embody, however are usually not restricted to, statements concerning: the $2 million growth milestone fee to Kazia; extra milestone funds of as much as $17 million upon the achievement of additional growth and regulatory milestones, plus sub-licensing revenues and royalties; the progress and enrollment of Sovargen’s Section 1b/2a scientific trial of paxalisib for FCD T2, TSC, and HME; the potential of paxalisib as a therapy for mTORopathy-related epilepsies and different non-oncology indications; and knowledge era from the scientific examine.
These forward-looking statements are based mostly on administration’s present expectations and assumptions as of the date of this press launch and are topic to important dangers, uncertainties, and different elements that might trigger precise outcomes to vary materially from these expressed or implied. Such dangers and uncertainties embody, however are usually not restricted to: dangers related to the event of early-stage therapeutic packages; the conduct and enrollment of scientific trials; regulatory evaluate and approval processes; reliance on third-party licensees, collaborators and trial websites; the Firm’s means to acquire, keep and defend its mental property; common financial and market circumstances; and the Firm’s means to take care of compliance with NASDAQ itemizing necessities.
For a extra full dialogue of dangers and uncertainties, please confer with the Firm’s filings with the SEC, together with the “Threat Elements” part of the Firm’s most up-to-date Annual Report on Type 20-F. The Firm undertakes no obligation to replace or revise any forward-looking statements, whether or not because of new data, future occasions, or in any other case, besides as required by regulation.
All forward-looking statements are certified of their entirety by this cautionary assertion.
